Rifaximin Decreases the Incidence and Severity of Acute Kidney Injury and Hepatorenal Syndrome in Cirrhosis.

Tien S DongAndrew AronsohnK Gautham ReddyHelen S Te

Published in: Digestive diseases and sciences (2016)

Long-term use of rifaximin is associated with a decrease incidence of AKI and HRS and a decrease risk of requiring RRT in a general population of cirrhotic patients.

Keyphrases

acute kidney injury
end stage renal disease
risk factors
ejection fraction
chronic kidney disease
newly diagnosed
cardiac surgery
prognostic factors
peritoneal dialysis
irritable bowel syndrome
patient reported outcomes